<DOC>
	<DOCNO>NCT02342015</DOCNO>
	<brief_summary>Background : Circulating osteoprogenitors RANKL expression immune cell implicate pathogenesis osteoporosis vascular calcification . The role play statin therapy bone-vascular axis unknown . Methods : Twenty naïve post-menopausal osteoporotic hypercholesterolemic woman treat Atorvastatin 40 mg/day three month . Blood sample collect baseline end treatment . Gene expression analysis perform assess modification OPG/RANK/RANKL expression isolate T-cells monocyte . A flow cytometry analysis use study change level circulate osteoprogenitor cell .</brief_summary>
	<brief_title>Effect Atorvastatin Bone-vascular Axis</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Newly diagnose osteoporosis ( T score ≤ 2.5 SD either lumbar spine femoral neck ) LDLcholesterol ≥ 130 mg/dl History bone fracture , Clinical evidence atherosclerotic disease CKD ( stage IIIV ) , Liver disease COPD Rheumatic disorder ; Current previous treatment statin , steroid , hormonal replacement therapy , antiosteoporotic drug ( include vitamin D calcium supplementation )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>